Rituximab In Combination With Chop (r-chop) Was Approved In 2006 By T

1.	Rituximab In Combination With Chop (r-chop) Was Approved In 2006 By The Fda For Treatment Of Diffuse Large B-cell Lymphoma (dlbcl). The Addition Of Rituximab To Standard Chemotherapy Has Been Shown To Benefit Which Patient Population?
Answer» AGE is an important issue in the treatment of patients with DLBCL because of the greater RISK for comorbid conditions. Therefore, strategies were initiated to use the IPI risk factors and the age-adjusted IPI in conjunction with stage, SERUM lactate dehydrogenase, and performance score as stratification factors to design THERAPEUTIC trials and appropriately select patients. These strategies were followed in the landmark R-CHOP trials, including the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and the US Intergroup Eastern Cooperative Oncology Group (ECOG) 4494/Cancer and Leukemia Group B (CALGB) 9793 trials. Results have shown that R-CHOP is effective in both older and YOUNGER patients and in low- and high-risk IPI groups. Age is an important issue in the treatment of patients with DLBCL because of the greater risk for comorbid conditions. Therefore, strategies were initiated to use the IPI risk factors and the age-adjusted IPI in conjunction with stage, serum lactate dehydrogenase, and performance score as stratification factors to design therapeutic trials and appropriately select patients. These strategies were followed in the landmark R-CHOP trials, including the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and the US Intergroup Eastern Cooperative Oncology Group (ECOG) 4494/Cancer and Leukemia Group B (CALGB) 9793 trials. Results have shown that R-CHOP is effective in both older and younger patients and in low- and high-risk IPI groups.

Rituximab In Combination With Chop (r-chop) Was Approved In 2006 By The Fda For Treatment Of Diffuse Large B-cell Lymphoma (dlbcl). The Addition Of Rituximab To Standard Chemotherapy Has Been Shown To Benefit Which Patient Population?

Answer»

AGE is an important issue in the treatment of patients with DLBCL because of the greater RISK for comorbid conditions. Therefore, strategies were initiated to use the IPI risk factors and the age-adjusted IPI in conjunction with stage, SERUM lactate dehydrogenase, and performance score as stratification factors to design THERAPEUTIC trials and appropriately select patients.

These strategies were followed in the landmark R-CHOP trials, including the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and the US Intergroup Eastern Cooperative Oncology Group (ECOG) 4494/Cancer and Leukemia Group B (CALGB) 9793 trials. Results have shown that R-CHOP is effective in both older and YOUNGER patients and in low- and high-risk IPI groups.

Age is an important issue in the treatment of patients with DLBCL because of the greater risk for comorbid conditions. Therefore, strategies were initiated to use the IPI risk factors and the age-adjusted IPI in conjunction with stage, serum lactate dehydrogenase, and performance score as stratification factors to design therapeutic trials and appropriately select patients.

These strategies were followed in the landmark R-CHOP trials, including the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and the US Intergroup Eastern Cooperative Oncology Group (ECOG) 4494/Cancer and Leukemia Group B (CALGB) 9793 trials. Results have shown that R-CHOP is effective in both older and younger patients and in low- and high-risk IPI groups.

Rituximab In Combination With Chop (r-chop) Was Approved In 2006 By The Fda For Treatment Of Diffuse Large B-cell Lymphoma (dlbcl). The Addition Of Rituximab To Standard Chemotherapy Has Been Shown To Benefit Which Patient Population?

Discussion

No Comment Found

Related InterviewSolutions

Reply to Comment